Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.

Mizugaki H, Hamada A, Shibata T, Hosoda F, Nakamura H, Okuma Y, Shukuya T, Umemura S, Horiike A, Fukui T, Kogure Y, Daga H, Urata Y, Yamada K, Saeki S, Fujisaka Y, Nakamura Y, Sato M, Yoshida T, Hotta T, Oizumi S, Fujiwara Y, Ohe Y, Fujiwara Y.

Lung Cancer. 2019 Feb;128:20-25. doi: 10.1016/j.lungcan.2018.12.002. Epub 2018 Dec 4.

PMID:
30642448
2.

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status.

Kitadai R, Okuma Y, Kawai S.

Onco Targets Ther. 2018 Dec 17;12:15-19. doi: 10.2147/OTT.S186213. eCollection 2019.

3.

Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).

Okuma Y, Morikawa K, Tanaka H, Yokoyama T, Itani H, Horiuchi K, Nakagawa H, Takahashi N, Bessho A, Soejima K, Kishi K, Togashi A, Kanai Y, Ueda K, Horimoto K, Matsutani N, Seki N.

Thorac Cancer. 2018 Dec 8. doi: 10.1111/1759-7714.12923. [Epub ahead of print]

PMID:
30536780
4.

Anti-High Mobility Group Box 1 Antibody Therapy May Prevent Cognitive Dysfunction After Traumatic Brain Injury.

Okuma Y, Wake H, Teshigawara K, Takahashi Y, Hishikawa T, Yasuhara T, Mori S, Takahashi HK, Date I, Nishibori M.

World Neurosurg. 2018 Nov 2. pii: S1878-8750(18)32462-8. doi: 10.1016/j.wneu.2018.10.164. [Epub ahead of print]

PMID:
30391757
5.

Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases.

Mitsuhashi A, Okuma Y, Zenke Y, Hosomi Y.

Mol Clin Oncol. 2018 Nov;9(5):561-565. doi: 10.3892/mco.2018.1710. Epub 2018 Sep 4.

6.

Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease.

Yoritaka A, Ohtsuka C, Maeda T, Hirayama M, Abe T, Watanabe H, Saiki H, Oyama G, Fukae J, Shimo Y, Hatano T, Kawajiri S, Okuma Y, Machida Y, Miwa H, Suzuki C, Kazama A, Tomiyama M, Kihara T, Hirasawa M, Shimura H, Oda E, Ito M, Ohno K, Hattori N.

Mov Disord. 2018 Sep;33(9):1505-1507. doi: 10.1002/mds.27472. Epub 2018 Sep 12. No abstract available.

PMID:
30207619
7.

Harmonization study of antibodies and platforms for programmed death ligand 1 immunostaining in non-small cell lung cancer: does shuffling couples settle the troubles?

Kashima J, Okuma Y.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2124-S2126. doi: 10.21037/jtd.2018.06.116. No abstract available.

8.

Correction to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.

Okuma Y, Hishima T, Kashima J, Homma S.

Cancer Immunol Immunother. 2018 Sep;67(9):1477-1479. doi: 10.1007/s00262-018-2215-z.

PMID:
30084040
9.

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.

Igawa S, Shirasawa M, Ozawa T, Nishinarita N, Okuma Y, Ono T, Sugimoto A, Kurahayashi S, Sugita K, Sone H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

Thorac Cancer. 2018 Aug;9(8):967-973. doi: 10.1111/1759-7714.12772. Epub 2018 Jun 5.

10.

Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.

Okuma Y, Wakui H, Utsumi H, Sagawa Y, Hosomi Y, Kuwano K, Homma S.

Clin Lung Cancer. 2018 Sep;19(5):410-417.e1. doi: 10.1016/j.cllc.2018.04.014. Epub 2018 May 5.

PMID:
29859759
11.

Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.

Okuma Y, Kashima J, Watanabe K, Homma S.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1601-1611. doi: 10.1007/s00432-018-2681-x. Epub 2018 Jun 1.

PMID:
29858682
12.

Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.

Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, Mitsufuji H, Kubota M, Hiyoshi Y, Ishihara M, Kasajima M, Sasaki J, Naoki K.

Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30103-7. doi: 10.1016/j.cllc.2018.04.021. [Epub ahead of print]

PMID:
29803573
13.

Response to "Immune-mediated cholangitis: is it always nivolumab's fault?"

Kashima J, Okuma Y.

Cancer Immunol Immunother. 2018 Aug;67(8):1329-1330. doi: 10.1007/s00262-018-2163-7. Epub 2018 Apr 26. No abstract available.

PMID:
29700568
14.

Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.

Nishinarita N, Igawa S, Kasajima M, Kusuhara S, Harada S, Okuma Y, Sugita K, Ozawa T, Fukui T, Mitsufuji H, Yokoba M, Katagiri M, Kubota M, Sasaki J, Naoki K.

Oncology. 2018;95(2):109-115. doi: 10.1159/000488594. Epub 2018 Apr 26.

PMID:
29698957
15.

COQ2 variants in Parkinson's disease and multiple system atrophy.

Mikasa M, Kanai K, Li Y, Yoshino H, Mogushi K, Hayashida A, Ikeda A, Kawajiri S, Okuma Y, Kashihara K, Sato T, Kondo H, Funayama M, Nishioka K, Hattori N.

J Neural Transm (Vienna). 2018 Jun;125(6):937-944. doi: 10.1007/s00702-018-1885-1. Epub 2018 Apr 11.

PMID:
29644397
16.

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.

Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group.

Oncologist. 2018 Oct;23(10):1210-1217. doi: 10.1634/theoncologist.2017-0586. Epub 2018 Mar 22.

PMID:
29567820
17.

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.

Hakozaki T, Okuma Y, Kashima J.

BMC Cancer. 2018 Mar 20;18(1):302. doi: 10.1186/s12885-018-4212-1.

18.

Microbial Degradation of Amino Acid-Containing Compounds Using the Microcystin-Degrading Bacterial Strain B-9.

Jin H, Hiraoka Y, Okuma Y, Hashimoto EH, Kurita M, Anas ARJ, Uemura H, Tsuji K, Harada KI.

Mar Drugs. 2018 Feb 6;16(2). pii: E50. doi: 10.3390/md16020050.

19.

Immune checkpoint inhibitors: the next step for thymic carcinomas.

Okuma Y.

Lancet Oncol. 2018 Mar;19(3):274-275. doi: 10.1016/S1470-2045(18)30064-0. Epub 2018 Jan 26. No abstract available.

PMID:
29395865
20.

Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.

Igawa S, Shirasawa M, Fukui T, Nishinarita N, Sone H, Ozawa T, Sugita K, Okuma Y, Kurahayashi S, Ono T, Sugimoto A, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K.

Oncology. 2018;94(4):207-214. doi: 10.1159/000486038. Epub 2018 Jan 31.

PMID:
29393275
21.

Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.

Kato Y, Kashima J, Watanabe K, Yomota M, Zenke Y, Okuma Y, Hosomi Y, Gemma A, Seike M, Okamura T.

Anticancer Res. 2018 Feb;38(2):1077-1083.

PMID:
29374744
22.

Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Mitsuhashi A, Okuma Y.

Clin Transl Oncol. 2018 Aug;20(8):966-974. doi: 10.1007/s12094-017-1827-7. Epub 2018 Jan 8. Review.

PMID:
29313208
23.

Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study.

Kashima J, Okuma Y, Murata H, Watanabe K, Hosomi Y, Hishima T.

J Thorac Dis. 2017 Oct;9(10):3911-3918. doi: 10.21037/jtd.2017.08.133.

24.

New histological classification and staging of thymic malignancies: ITMIG consensus statements and the 8th TNM staging system.

Kashima J, Okuma Y.

J Thorac Dis. 2017 Oct;9(10):3656-3658. doi: 10.21037/jtd.2017.09.126. No abstract available.

25.

High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.

Okuma Y, Hishima T, Kashima J, Homma S.

Cancer Immunol Immunother. 2018 Mar;67(3):495-505. doi: 10.1007/s00262-017-2103-y. Epub 2017 Dec 14. Erratum in: Cancer Immunol Immunother. 2018 Sep;67(9):1477-1479.

PMID:
29243049
26.

A prospective study of falls in relation to freezing of gait and response fluctuations in Parkinson's disease.

Okuma Y, Silva de Lima AL, Fukae J, Bloem BR, Snijders AH.

Parkinsonism Relat Disord. 2018 Jan;46:30-35. doi: 10.1016/j.parkreldis.2017.10.013. Epub 2017 Oct 19.

PMID:
29079421
27.

The prevalence, course and clinical correlates of migraine in Parkinson's disease: A multicentre case-controlled study.

Suzuki K, Okuma Y, Uchiyama T, Miyamoto M, Sakakibara R, Shimo Y, Hattori N, Kuwabara S, Yamamoto T, Kaji Y, Hirano S, Suzuki S, Haruyama Y, Kobashi G, Hirata K; Kanto NMPD investigators.

Cephalalgia. 2018 Aug;38(9):1535-1544. doi: 10.1177/0333102417739302. Epub 2017 Oct 26.

PMID:
29073773
28.

Chronic subdural haematoma presenting as freezing of gait.

Noda K, Hattori N, Okuma Y, Yamamoto T.

BMJ Case Rep. 2017 Sep 26;2017. pii: bcr-2017-221469. doi: 10.1136/bcr-2017-221469.

PMID:
28951429
29.

Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.

Kashima J, Okuma Y, Shimizuguchi R, Chiba K.

Cancer Immunol Immunother. 2018 Jan;67(1):61-65. doi: 10.1007/s00262-017-2062-3. Epub 2017 Sep 14.

PMID:
28913619
30.

Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study.

Suzuki K, Okuma Y, Uchiyama T, Miyamoto M, Sakakibara R, Shimo Y, Hattori N, Kuwabara S, Yamamoto T, Kaji Y, Hirano S, Kadowaki T, Hirata K; Kanto NMPD investigators.

J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):953-959. doi: 10.1136/jnnp-2017-316136. Epub 2017 Aug 28.

31.

Characterizing restless legs syndrome and leg motor restlessness in patients with Parkinson's disease: A multicenter case-controlled study.

Suzuki K, Okuma Y, Uchiyama T, Miyamoto M, Sakakibara R, Shimo Y, Hattori N, Kuwabara S, Yamamoto T, Kaji Y, Hirano S, Numao A, Hirata K; Kanto NMPD investigators.

Parkinsonism Relat Disord. 2017 Nov;44:18-22. doi: 10.1016/j.parkreldis.2017.08.007. Epub 2017 Aug 14.

PMID:
28827009
32.

The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study.

Ouma S, Fukae J, Fujioka S, Yamamoto S, Hatano T, Yoritaka A, Okuma Y, Kashihara KI, Hattori N, Tsuboi Y.

Intern Med. 2017;56(15):1961-1966. doi: 10.2169/internalmedicine.56.7667. Epub 2017 Aug 1.

33.

Involvement of endoplasmic reticulum stress and neurite outgrowth in the model mice of autism spectrum disorder.

Kawada K, Mimori S, Okuma Y, Nomura Y.

Neurochem Int. 2018 Oct;119:115-119. doi: 10.1016/j.neuint.2017.07.004. Epub 2017 Jul 12.

PMID:
28711654
34.

Falling Direction can Predict the Mechanism of Recurrent Falls in Advanced Parkinson's Disease.

Youn J, Okuma Y, Hwang M, Kim D, Cho JW.

Sci Rep. 2017 Jun 20;7(1):3921. doi: 10.1038/s41598-017-04302-7.

35.

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature.

Nakahara Y, Fukui T, Katono K, Nishizawa Y, Okuma Y, Ikegami M, Sasaki J, Masuda N.

Case Rep Oncol. 2017 Apr 18;10(1):333-338. doi: 10.1159/000463380. eCollection 2017 Jan-Apr.

36.

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.

Misumi Y, Okamoto H, Sasaki J, Masuda N, Ishii M, Shimokawa T, Hosomi Y, Okuma Y, Nagamata M, Ogura T, Kato T, Sata M, Otani S, Takakura A, Minato K, Miura Y, Yokoyama T, Takata S, Naoki K, Watanabe K.

BMC Cancer. 2017 May 26;17(1):377. doi: 10.1186/s12885-017-3353-y.

37.

Single-institutional experience of clinicopathological analysis and treatment for lung cancer patients with human immunodeficiency virus infection.

Takahashi S, Okuma Y, Watanabe K, Hosomi Y, Imamura A, Okamura T, Gemma A.

Mol Clin Oncol. 2017 May;6(5):765-769. doi: 10.3892/mco.2017.1214. Epub 2017 Apr 6.

38.

Acute pancreatitis caused by pancreatic ischemia after TEVAR combined with intentional celiac artery coverage and embolization of the branches of the celiac artery.

Kawatani Y, Kurobe H, Nakamura Y, Suda Y, Okuma Y, Sato S, Hashimoto T, Hori T.

J Surg Case Rep. 2017 Feb 23;2017(2):rjx029. doi: 10.1093/jscr/rjx029. eCollection 2017 Feb.

39.
40.

Thymic Carcinoma With Endobronchial Metastasis: A Case Report.

Nagamata M, Okuma Y, Hosomi Y, Hishima T.

J Bronchology Interv Pulmonol. 2017 Apr;24(2):159-162. doi: 10.1097/LBR.0000000000000254.

PMID:
28323731
41.

Freezing of gait and fall detection in Parkinson's disease using wearable sensors: a systematic review.

Silva de Lima AL, Evers LJW, Hahn T, Bataille L, Hamilton JL, Little MA, Okuma Y, Bloem BR, Faber MJ.

J Neurol. 2017 Aug;264(8):1642-1654. doi: 10.1007/s00415-017-8424-0. Epub 2017 Mar 1. Review.

42.

Interleaved neuromuscular electrical stimulation after spinal cord injury.

Bergquist AJ, Wiest MJ, Okuma Y, Collins DF.

Muscle Nerve. 2017 Nov;56(5):989-993. doi: 10.1002/mus.25634. Epub 2017 Apr 4.

PMID:
28245521
43.

Erratum to: A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.

Yoritaka A, Abe T, Ohtsuka C, Maeda T, Hirayama M, Watanabe H, Saiki H, Oyama G, Fukae J, Shimo Y, Hatano T, Kawajiri S, Okuma Y, Machida Y, Miwa H, Suzuki C, Kazama A, Tomiyama M, Kihara T, Hirasawa M, Shimura H, Hattori N.

BMC Neurol. 2017 Feb 20;17(1):35. doi: 10.1186/s12883-017-0817-2. No abstract available.

44.

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.

Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S.

Lung Cancer. 2017 Feb;104:1-6. doi: 10.1016/j.lungcan.2016.11.023. Epub 2016 Dec 5.

PMID:
28212990
45.

Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.

Kashima J, Okuma Y, Miwa M, Hosomi Y.

Jpn J Clin Oncol. 2017 Apr 1;47(4):357-362. doi: 10.1093/jjco/hyw206.

PMID:
28064206
46.

Hemichorea improvement following endarterectomy for internal carotid artery stenosis.

Noda K, Ishimoto R, Hattori N, Okuma Y, Yamamoto T.

J Neurol Sci. 2016 Dec 15;371:45-47. doi: 10.1016/j.jns.2016.10.019. Epub 2016 Oct 14. No abstract available.

PMID:
27871446
47.
48.

Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease - A Multicenter Retrospective Study.

Okuma Y, Suda K, Nakaoka H, Katsube Y, Mitani Y, Yoshikane Y, Ichida F, Matsushita T, Shichino H, Shiraishi I, Abe J, Hiroe M, Yoshida T, Imanaka-Yoshida K.

Circ J. 2016 Oct 25;80(11):2376-2381. Epub 2016 Oct 15.

50.

A Case of Painless Legs and Moving Toes Syndrome in Parkinson's Disease Responsive to Dopaminergic Therapy.

Kawajiri S, Hoshino Y, Nakamura R, Noda K, Tomizawa Y, Hattori N, Okuma Y.

Case Rep Neurol Med. 2016;2016:6829410. doi: 10.1155/2016/6829410. Epub 2016 Aug 28.

Supplemental Content

Support Center